Please login to the form below
Tudorza
This page shows the latest Tudorza news and features for those working in and with pharma, biotech and healthcare.
Circassia seeks shift to AIM after failing LSE criteria
AZ’s booked sales for Tudorza fell more than 50% to $18m in the third quarter. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon approval of Duaklir, plus a deferred consideration of $100m.
Latest news
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
-
AZ adds to respiratory portfolio with Actavis drugs
Tudorza Pressair (aclidinium bromide inhalation powder) is a long-acting muscarinic antagonist (LAMA) Tudorza Pressair (aclidinium bromide inhalation powder) and Daliresp (roflumilast) is a once-daily oral PDE4 inhibitor. ... Paul Hudson, the head of
-
Forest said to be interested in $3bn Aptalis acquisition
The company is looking to new products such as chronic obstructive pulmonary disease (COPD) therapy Tudorza (aclidinium bromide), launched at the end of 2012, and irritable bowel syndrome drug Linzess (linaclotide)
-
Forest and Almirall delay FDA filing of COPD drug
The drug is a combination of Forest's long-acting muscarinic antagonist (LAMA) Tudorza (aclidinium bromide) and Astellas' long-acting beta agonist (LABA) formoterol fumarate.
-
FDA advisors back Boehringer's COPD drug olodaterol
Forest launched aclidinium bromide as a monotherapy in the US under the Tudorza brand name towards the end of last year.
More from news
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
- Man vs microbe: the fight against antimicrobial resistance
- Dollo's law
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
- HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
- In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....
